Streptococcus gallolyticus subspecies gallolyticus (SGG) is potentially associated with colorectal cancer (CRC) and its precursors. A previous case-control study measured antibody responses to SGG pilus proteins Gallo2178 and Gallo2179 and identified significant associations with a small fraction of CRC cases. We aimed at replicating and expanding these findings in an independent study including additional SGG antigens and explored the association with precancerous lesions. We applied multiplex serology to measure antibodies to eleven SGG proteins in serum samples of a screening colonoscopy trial (BliTz study) including participants diagnosed with either non-advanced adenoma (NAA, n 5 30), advanced adenoma (AA, n 5 100), CRC (n 5 50) or controls (n 5 228). In addition, we analyzed CRC samples (n 5 318) from patients recruited in a clinical setting (DACHSplus study). The association of antibody responses to SGG pilus proteins Gallo2178 and Gallo2179 with CRC was replicated with 4% positive DACHSplus cases compared to 0% positive BliTz controls. Positivity to two or more proteins of a newly defined panel of six SGG markers was significantly associated with CRC in the DACHSplus study (OR: 1.81, 95% CI: 1.07-3.06). Odds for CRC, AA and NAA in the BliTz study were also increased with antibody responses to SGG, and the association was significant for NAA (OR: 2.98, 95% CI: 1.18-7.57). Antibody responses to SGG are associated with CRC and its precursors. The newly identified SGG six-marker panel and associations found with precancerous lesions should be further explored.
Streptococcus gallolyticus subspecies gallolyticus (SGG) is potentially associated with colorectal cancer (CRC) and its precursors. A previous case-control study measured antibody responses to SGG pilus proteins Gallo2178 and Gallo2179 and identified significant associations with a small fraction of CRC cases. We aimed at replicating and expanding these findings in an independent study including additional SGG antigens and explored the association with precancerous lesions. We applied multiplex serology to measure antibodies to eleven SGG proteins in serum samples of a screening colonoscopy trial (BliTz study) including participants diagnosed with either non-advanced adenoma (NAA, n 5 30), advanced adenoma (AA, n 5 100), CRC (n 5 50) or controls (n 5 228). In addition, we analyzed CRC samples (n 5 318) from patients recruited in a clinical setting (DACHSplus study). The association of antibody responses to SGG pilus proteins Gallo2178 and Gallo2179 with CRC was replicated with 4% positive DACHSplus cases compared to 0% positive BliTz controls. Positivity to two or more proteins of a newly defined panel of six SGG markers was significantly associated with CRC in the DACHSplus study (OR: 1.81, 95% CI: 1.07-3.06). Odds for CRC, AA and NAA in the BliTz study were also increased with antibody responses to SGG, and the association was significant for NAA (OR: 2.98, 95% CI: 1.18-7.57). Antibody responses to SGG are associated with CRC and its precursors. The newly identified SGG six-marker panel and associations found with precancerous lesions should be further explored.
Colorectal cancer (CRC) is the third most common cancer and the fourth most common cause of cancer death worldwide with 1.3 million new cases and almost 700,000 deaths in 2012. 1 Well known risk factors for CRC are increasing age, male gender, smoking, high alcohol consumption, family history of CRC, inflammatory diseases of the gut, diabetes and obesity. In contrast, regular intake of aspirin as an antiinflammatory drug is protective. 2 Chronic inflammation as one of the major CRC risk factors led to the assumption that infections might be involved in development and/or progression of the disease. Several metagenomic studies analyzed the composition of the human intestinal microbiome and found that shifts in the level of bacterial taxa might be indicative for CRC. 3, 4 A different approach compared to comprehensive but also highly timeand cost-intensive metagenomic studies is to assess the association of specific bacterial species with CRC. An interesting candidate in this respect is the opportunist Streptococcus gallolyticus subspecies gallolyticus (SGG). The bacterial species Streptococcus bovis (S. bovis) has already been described in the 1970's to be connected to colorectal neoplasms: Infective endocarditis induced by this bacterium co-occurred in several reports with the presence of intestinal adenoma. [5] [6] [7] In 1989, it was postulated for the first time that especially one S. bovis subspecies (biotype I, later renamed to SGG), was the inducer of adenoma-associated infective streptococcal endocarditis. 8 Since then different case reports and case series replicated the finding of CRC or its precursors present in SGG-induced bacteremia/infective endocarditis patients at a higher rate compared to bacteremia/infective endocarditis induced by other bacteria. 9 It is hypothesized that SGG is able to invade intestinal tissue upon formation of colorectal neoplasm and the subsequent changes in the microenvironment of the tissue. It then may enter the bloodstream and cause bacteremia and/or infective endocarditis. 10 Thus, antibody response against the infecting SGG may be used as a marker for the presence of colorectal neoplasms. Few case-control studies were conducted so far using different serological methods to verify this hypothesis. [11] [12] [13] [14] [15] [16] A Spanish case-control study performed in our laboratory showed 3.6-fold increased odds of CRC with high antibody levels against SGG pilus proteins Gallo2178 and Gallo2179. 16 However, only 4% of CRC cases were positive to both, Gallo2178 and Gallo2179, compared to 1% of positive controls.
Multiplex serology provides an easy-to-apply and costeffective methodology to measure antibody responses to several antigens in one reaction. 17 Specific serological markers for Human Papillomavirus-induced head-and-neck cancer 18 but also Helicobacter pylori-induced gastric cancer 19 were previously identified using this technique highlighting the ability of multiplex serology to identify markers for infectionassociated cancers.
In this study, we applied multiplex serology with a panel of eleven SGG proteins, including Gallo2178 and Gallo2179, to reproduce and expand the previously published finding of an association between CRC and antibody responses to SGG 16 in an independent German case-control study. We also assessed the association of antibody responses to SGG with different stages of colorectal neoplasm, that is, non-advanced adenoma (NAA), advanced adenoma (AA) and CRC.
Methods

Study population
The design for this study was described previously. 20 Briefly, one group of serum samples included was a subset of the BliTz study (Begleitende Evaluierung innovativer Testverfahren zur Darmkrebsfr€ uherkennung), 21, 22 for which participants were recruited at screening colonoscopy in gastroenterology practices in southern Germany. Prior to colonoscopy, patients also provided blood samples for further analyses. The subset included all 50 newly identified CRC cases as well as randomly selected 30 NAA cases, 100 AA cases and 228 controls with no colorectal neoplasm that were recruited between 2005 and 2013. Adenomas with high grade dysplasia (HGD), villous architecture without HGD, or large adenomas ( 10 mm) with neither HGD nor villous architecture were considered AA, whereas adenomas < 10 mm with tubular architecture or without HGD were considered NAA. 20 To increase the number of CRC cases, we also included a separate case group of 318 CRC cases of the DACHSplus study, a substudy of the case-control study DACHS (Darmkrebs: Chancen der Verh€ utung durch Screening), in which participants were recruited after diagnosis but before surgery at four hospitals in Southern Germany between 2003 and 2007. 23 Since the initial design was conducted to resemble a true screening setting, CRC cases and precursors were not matched to controls by age and gender. 20, 24 SGG multiplex serology Sera were sent on dry ice to the Division of Molecular Diagnostics of Oncogenic Infections, DKFZ, Heidelberg, and analyzed in a 1:100 dilution for antibodies against SGG using multiplex serology, a serological tool that allows for quantification of antibodies simultaneously against up to 100 separate antigens. 17 Eleven SGG (strain UCN34) proteins were selected as antigens in multiplex serology (Table 1) .
Selection was based (i) on previous findings suggesting immunogenicity 13 and (ii) on localization of the proteins on the outside of the bacterium (secreted, cell wall-attached). 16, 25 Specificity for SGG was addressed by analysing the amino acid sequences of the selected antigens for homologues using "BLASTp" 26 with the majority of proteins having <70% sequence identity to proteins of other bacteria (Table 1) . Selected genes were synthesized and subcloned into the expression vector pGEX4T3tag 27 by eurofins (Ebersberg, Germany). Proteins of interest (X) are flanked by an N-terminal Glutathione-S-transferase (GST) and a C-terminal tag (C-terminal undecapeptide of simian virus 40 large T-antigen). GST-X-tag fusion proteins were expressed in Escherichia coli BL21 and lysates prepared as described. 27 Recombinant GST-X-tag fusion proteins were affinity-purified on glutathionecoupled fluorescent beads filled with two dyes at different ratios to provide an array of 100 different bead sets (SeroMap, Luminex Corp., Austin, TX). Mixing of bead sets carrying different antigens resulted in a suspension antigen array that was presented to sera. A Luminex xMAP (Luminex Corp., Austin, TX) analyzer identified the bead set and consequently the loaded antigen. Bound serum antibodies were stained by biotinylated goat anti human-IgA, IgM and IgG and fluorescent reporter conjugate Streptavidin-RPhycoerythrin. The level of antibody response is given as median fluorescence intensity (MFI) on at least 100 beads per set. 17 Net MFI values were generated by subtracting background responses against the N-Terminal GST and the CTerminal tag as well as against the bead-surface. Capsid protein VP1 of the Polyomavirus JC (up to 80% seroprevalence) 28 was used as positive control antigen. There is no gold standard serological assay available to validate the newly developed SGG multiplex serology. However, the distribution of MFI measured to individual SGG proteins among controls reflected the low fecal carriage rate
What's new?
This study presents the development of a multiplex serology for the detection of antibodies to Streptococcus gallolyticus subspecies gallolyticus (SGG) and its application in a German colorectal cancer and precursor case-control study. Antibody responses to a newly identified six-marker panel of SGG antigens are associated with presence of CRC and precursor lesions detecting up to 27% of cases and could serve as marker for CRC already at an early stage of disease.
of SGG among the healthy population, which in crosssectional studies ranged between 1% to 11% 29, 30 : MFI values obtained with SGG proteins were low as compared to Polyomavirus JC VP1 28 (Supporting Information Fig. S1 ). In the absence of direct gold standard-based SGG infection data, we arbitrarily defined cut-offs based on the highest antibody responses (upper 10th percentile) among controls. The technical minimum cut-off was 30 MFI (Table 1) .
Statistical analyses
Differences between controls and CRC cases as well as risk factors (age, sex, BMI, smoking, education and family history of CRC) for any of the eleven SGG proteins were analyzed using Pearson's v 2 -test. We estimated the association of antibody responses to SGG proteins with CRC (DACHSplus) in reference to BliTz controls using logistic regression models to compute odds ratios (OR) and 95% confidence intervals (95% CI). Since BliTz controls and DACHSplus cases were not matched for age and gender, two major risk factors for CRC development, these two variables were included in a multivariate model for adjustment. We first attempted to validate previous findings on the association of antibody responses to Gallo2178 and Gallo2179 with CRC and then further explored antibody responses to the additional SGG proteins included in SGG multiplex serology. In addition to evaluating positivity to individual proteins as well as to any of the eleven SGG proteins, we tested whether antibody-positivity to SGG proteins correlates by performing Pearson's v 2 tests. Furthermore, we constructed an exploratory six-marker panel including all two-marker combinations, in which antibody-positivity to SGG proteins correlated and where the fraction of doublepositive cases exceeded that of double-positive controls at least two-fold. Multiple testing was addressed using Bonferroni-correction. Within total 14 definitions for antibody positivity (eleven individual SGG proteins, positivity to any SGG protein, positivity to two or more proteins of the identified six-marker panel as well as double-positivity to Gallo2178-Gallo2179) the p values for significance was adjusted to 0.004.
To verify observed associations in a different set of CRC cases and precursor lesions we estimated the association of antibody responses to SGG proteins with NAA, AA and CRC cases in the BliTz study. Separate logistic regression models with adjustment for age and gender were applied for the individual disease groups in reference to BliTz controls.
All statistical analyses were performed using the SAS 9.3 software (SAS Institute Inc., Cary, NC).
Results
Study characteristics
BliTz controls had a higher educational level than AA cases, were less frequent males, ever smokers and were of younger age than BliTz and DACHSplus CRC cases ( Table 2) .
Replication of the serological association of Gallo2178 and Gallo2179 with DACHSplus CRC cases compared to BliTz controls
In a previous CRC case-control study we identified an association of CRC with antibody responses to Gallo2178 and Gallo2179 individually but also with double-positivity to these two proteins. 16 In the study presented here, we first attempted to validate this finding (Table 3) . Antibody responses to Gallo2178 in controls were almost completely absent: <10% of controls had an MFI greater 1. Using the 3 With exclusion of S. equinus, close bacterial relative to SGG, rarely isolated from humans; % query: percent of query coverage that overlaps the subject sequence; % identity: percent similarity between the query and subject sequences over the coverage area.
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Gender
Female 124 (54)
13 (43) 50 (50) 16 (32) 133 ( 12 (40) 38 (38) 10 (20) 83 (26) 61-65
51 (22) 6 (20) 23 (23) 14 (28) 47 ( 89 (40) 8 (27) 37 (38) 12 (24) 118 (38) 25-29.9
95 (42) 15 (50) 40 (41) 25 (52) 134 ( We further assessed whether double-positivity to Gallo2178 and Gallo2179 was associated with CRC in this study. None of the controls was double-positive for Gallo2178-Gallo2179 compared to 4% of DACHSplus cases (association not estimable). However, crude analysis using a v 2 test showed that CRC prevalence and Gallo2178-Gallo2179 double-positivity were significantly associated, even after correction for multiple testing (p values 0.001).
Exploration of the association of CRC with antibody responses to newly developed SGG antigens in DACHSplus cases compared to BliTz controls
Only a minor fraction of CRC cases was positive to Gallo2178 (17%) and Gallo2178-Gallo2179 (4%) ( Table 3) . We also explored additional SGG proteins and analyzed whether antibody responses to these proteins individually or in combination are associated with CRC.
Positivity to any of the in total eleven proteins was not associated with any potential risk factor among BliTz controls (Supporting Information Table S1 ).
Comparing the fraction of DACHSplus CRC cases positive to any of the eleven SGG proteins (67%) to those among BliTz controls (57%) we found a positive association of positivity to any SGG protein with CRC (OR: 1.47, 95% CI: 1.02-2.12, p values 0.023). The OR for positivity to most of the individual proteins ranged around the null value of 1.0 with Gallo1570 being negatively associated with CRC (OR: 0.45, 95% CI: 0.22-0.91, p values 0.037; Fig. 1a) .
We further explored whether antibody responses to proteins of the newly developed SGG antigen panel correlate, comparably to Gallo2178 and Gallo2179, and whether this might strengthen the observed association with CRC. Since it is hypothesized that the presence of colorectal neoplasm is a prerequisite for SGG infection followed by seroconversion, we assessed whether correlations between antibody responses to individual proteins occur preferentially among CRC cases compared to controls (Supporting Information Table S2 ). Several SGG marker combinations in addition to Gallo2178-Gallo2179 were identified, where antibody responses correlated and where the fraction of double-positive cases exceeded that of double-positive controls at least two-fold: Gallo0272-Gallo0748 (3.4-fold), Gallo0272-Gallo1675 (2.8-fold) and Gallo2018-Gallo2179 (2.2-fold). Combining these proteins in a six-marker panel and defining SGG positivity as being positive to two or more proteins of this panel resulted in a positive association with CRC (OR: 1.81, 95% CI: 1.07-3.06, p values 0.008; Fig. 1a ). The fraction of controls positive to two or more proteins of the six-marker panel was 11% compared to 19% of CRC cases.
Associations between antibody responses to SGG proteins and CRC and precursors in BliTz case groups
In addition to DACHSplus CRC cases we analyzed a subset of the BliTz case groups identified during colonoscopy screening. These did not only include 50 CRC cases but also precursor lesions including 30 NAA as well as 100 AA. BliTz case groups were analyzed for associations with positivity to individual SGG proteins, to any of the eleven proteins, to two or more proteins of the six-marker panel as well as for double-positivity to Gallo2178-Gallo2179 to validate and extend findings with CRC cases from DACHSplus (Fig. 1b) . BliTz CRC cases were associated with positivity to Gallo2178 (OR: 3.19; 95% CI: 1.11-9.21, p values 0.017). The fraction of BliTz CRC cases positive to any of the eleven SGG proteins (68%) and to two or more proteins of the six-marker panel (16%) resembled those in DACHSplus cases, however, associations were not significant (OR: 1.27; 95% CI: 0.64-2.51 and OR: 1.50; 95% CI: 0.61-3.72, respectively). None of the BliTz CRC cases was double-positive to Gallo2178-Gallo2179.
AA cases showed a different antibody pattern with a significant association with positivity to Gallo0933 (OR: 2.02; 95% CI: 1.01-4.04, p values 0.048) and an inverse but insignificant association with positivity to Gallo2178 (OR: 0.54, 95% CI: 0.15-2.03). AA were not significantly associated with positivity to any SGG protein or to two or more of the sixmarker panel (OR: 1.35; 95% CI: 0.82-2.21 and OR: 1.33; 95% CI: 0.65-2.74, respectively). In addition, only 2% of AA were double-positive to Gallo2178-Gallo2179 compared to 0% of controls. Odds for NAA were significantly increased with positivity to Gallo2179 at the 95% confidence level (OR: 3.31, 95% CI: 1.24-8.84, p values 0.026) but not to Gallo2178 (OR: 2.13; 95% CI: 0.55-8. 19 ). Positivity to any of the eleven SGG proteins was not associated with NAA (OR: 1.39; 95% CI: 0.63-3.19). Positivity to two or more proteins of the six-marker panel, however, resulted in a positive association with NAA (OR: 2.98, 95% CI: 1.18-7.57, 0.013). With this marker panel we were able to detect 27% SGG-positives among NAA compared to 11% of controls. Additionally, 7% of NAA were double-positive to Gallo2178-Gallo2179, compared to 0% of controls (p values < 0.0001).
Discussion
In this German CRC case-control study, we were able to replicate and expand findings of an independent CRC casecontrol study 16 on the serological association of SGG with CRC. We replicated the association of antibody responses to two SGG proteins (Gallo2178 and Gallo2179) and identified four additional SGG proteins that in combination with Gallo2178 and Gallo2179 were associated with CRC and its precursor lesion NAA.
Two SGG proteins, Gallo2178 and Gallo2179, were previously reported to be associated with CRC. In our previous study 16 double-positivity to Gallo2178 and Gallo2179 resulted in a significant OR of 3.6 with 4% positive CRC cases compared to 1% positive controls. We reproduced this finding with this independent study, both, with individual responses to Gallo2178 and double-positivity to Gallo2178 and Gallo2179. Among DACHSplus CRC cases, 4% were double-positive to Gallo2178 and Gallo2179 in contrast to 0% in BliTz controls. Gallo2178 and Gallo2179 are pilus proteins that are assumed to be virulence factors in SGG-induced infective endocarditis but also in invasion of CRC tissue. 13, 31 Antibody responses to two other putative pilus proteins, Gallo0577 and Gallo1570, were not associated with CRC. Both proteins do not possess the same collagen binding motif as Gallo2179, which may result in a lowered relevance for tissue invasion. 32 Proteins Gallo2178 and Gallo2179 are expressed from the same operon and are both part of the pil1 pilus structure with Gallo2178 being the backbone protein of the pilus and Gallo2179 the tip protein supposed to be important for adhesion to host tissue. Pil1 in a mouse model has been identified as the first SGG endocarditis virulence factor. 31 In humans SGG endocarditis is clinically associated with CRC. While antibody responses to Gallo2178 were significantly associated with CRC in this study, responses to Gallo2179 were not. Among controls antibody responses to Gallo2179 were more frequent and stronger than those to Gallo2178 (Supporting Information Fig. S1 ) indicating that antibody responses to Gallo2178 might develop more specifically in the process of CRC development, for example in the presence of SGG strains with stronger pil1 expression and thus potentially better colonization.
We also explored the diagnostic value of serological marker combinations. Since the combination of Gallo2178-Gallo2179 double-positivity was highly CRC-specific but the fraction of cases with this marker combination was rather low we explored additional combinations for their capacity to increase sensitivity for CRC without losing specificity. Antibody responses might differ between infected individuals since (i) antibody responses might be directed against different proteins dependent on the individual and/or (ii) the infecting SGG might be of a distinct strain expressing a different set of proteins presented to the immune system. We identified four other SGG proteins that correlate pairwise and where the fraction of double-positive individuals among DACHSplus CRC cases exceeded that of controls at least twofold: Gallo0272-Gallo0748, Gallo0272-Gallo1675 and Gallo2018-2179. So far, functions of the newly identified proteins were only predicted by amino acid similarities to proteins of other bacterial species: (i) Gallo0272 is a putative agglutinin receptor. The here expressed domain resembles a glucan binding protein C domain. Agglutinin receptors in the oral bacterium Streptococcus gordinii mediate binding to host cell and bacterial receptors and may represent important virulence factors. 33 (ii) Gallo0748 is supposed to have an endopeptidase function, which is important in protein turnover. 34 (iii) Gallo2018 is putatively involved in bacteriocin synthesis, inhibiting the growth of other bacteria in the surrounding and thereby mediating a growth advantage. 34 (iv) Gallo1675 is a cell wall protein with unknown function 34 . Combining the proteins resulted in a six-marker panel. Positivity to two or more proteins of this six-marker panel led to a significant OR of 1.8 with DACHSplus CRC cases.
In addition to DACHSplus CRC cases we analyzed the association of antibody responses to SGG proteins in case groups of the BliTz study. These included a subset of NAA (n 5 30), AA (n 5 100) as well as CRC (n 5 50) newly diagnosed during colonoscopy screening.
Double-positivity to Gallo2178-Gallo2179 was a rare event in DACHSplus cases (4%) and could not be identified in any of the 50 BliTz CRC cases. However, we were able to replicate the association of positivity to Gallo2178 found with DACHSplus cases also with BliTz CRC (fourfold compared to threefold increased odds, respectively). The associations of antibodies to SGG proteins with precancerous lesions differed: antibody responses to Gallo2178 as a single marker were not significantly associated with NAA, whereas odds for NAA were significantly three-fold increased with positivity to Gallo2179. NAA cases were also associated with doublepositivity to Gallo2178-Gallo2179 and positivity to two or more proteins of the six-marker panel. The association was even stronger than that with DACHSplus CRC cases (threefold compared to 1.8-fold increased odds) with 27% of NAA positive for the six-marker panel compared to 11% positive controls. These results are in line with a study by GarzaGonz alez et al., 14 in which a Western Blot based on whole lysate from SGG was applied to sera from 133 patients with adenomatous polyps and 53 polyp-free controls. They identified fractions, similar to our data, of SGG-antibody positive individuals with 29% positive polyp patients compared to 13% positive controls.
Overall, associations of AA with antibody responses to SGG proteins were weaker than with NAA but also CRC. AA cases showed an association with positivity to Gallo0933, a putative tannase, 32 but not Gallo2178. In addition there was no significant association with double-positivity to Gallo2178-Gallo2179, positivity to any SGG protein or to two or more proteins of the six-marker panel. The adenomacarcinoma pathogenesis sequence for CRC indicates the formation of an early adenoma as starting point for tumor formation followed by acquisition of several mutations leading to AA and finally CRC. If the adenoma-carcinoma sequence holds true and the SGG infection remains in the tumor tissue we would expect similar antibody pattern as seen with NAA and CRC also in AA cases. This, however, was not the case in this study. Reasons for this phenomenon might be of statistical or, more speculative, of biological nature: (i) sample sizes in the BliTz case groups were very small (NAA n 5 30, AA n 5 100, CRC n 5 50) and antibody responses to SGG, especially double-positivity to Gallo2178-Gallo2179 was a rare event. Resulting imprecision in the estimates might account for the difference in the association between the case groups; (ii) The AA included in the BliTz study differed from NAA and CRC cases in one or more unknown risk factors for SGG that we currently cannot assess; (iii) there might be different types of early intestinal lesions that fall under the definition of NAA but do not follow the typical adenoma-CRC sequence, like for example the serrated pathway. 35 Larger studies should be conducted to assess the statistical component. Under the assumption that we tested 14 different combinations for SGG antibody positivity a Bonferroni-corrected p values for significance would be 0.004. None of the estimates, except those for positivity to Gallo2178 in DACHSplus cases and double-positivity to Gallo2178-Gallo2179 in DACHSplus cases and BliTz NAA, here reached such a significance level and studies with more statistical power are needed to assess the significance of the observed associations. Eventually further to be explored biological possibilities need studies with more specific information on the type of colorectal neoplasm but also more comprehensive questionnaires including factors that may influence the composition of the intestinal microbiome, for example, diet, antibiotics and anti-inflammatory drug use. 36 In conclusion, we were able to replicate the association of antibody responses to SGG proteins, especially Gallo2178 and Gallo2179, in an independent CRC case-control study. We expanded the findings by increasing the number of SGG proteins specifically associated with CRC and precursors to a six-marker panel. A clear limitation of this study is the small sample size, especially in the group of NAA cases. However, results with regard to the potential of SGG serology as a marker especially in early precancerous lesions should be further explored and validated in a larger sample set.
